Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) rose 1.3% during mid-day trading on Monday . The company traded as high as $1.60 and last traded at $1.57. Approximately 62,855 shares traded hands during trading, a decline of 91% from the average daily volume of 711,689 shares. The stock had previously closed at $1.55.
Salarius Pharmaceuticals Trading Up 1.3 %
The firm has a market cap of $2.26 million, a price-to-earnings ratio of -0.19 and a beta of 0.92. The firm’s 50-day moving average is $1.52 and its 200-day moving average is $1.91.
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Recommended Stories
- Five stocks we like better than Salarius Pharmaceuticals
- Profitably Trade Stocks at 52-Week Highs
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- What is the S&P/TSX Index?
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- How to trade using analyst ratings
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
